

# WaveData

## COMMERCIAL BULLETIN

**Wavedata' s bulletin is a free on charge service, if you have any colleagues that would like to receive the bulletin please let us know.**

**As always, please contact us if you require additional information or if we can be of further assistance in product/products you would like to see in our database.**

**If this is of interest to you, or you have preferences on what products you would like to see please email: [bulletin@wavedata.co.uk](mailto:bulletin@wavedata.co.uk)**



## **NEW PIP CODES FOR NORTHERN IRELAND POST-BREXIT**

Under the terms of the Northern Ireland protocol, which is part of the Brexit deal, Northern Ireland has remained in the EU's single market for goods. Since January 2021, the protocol has mandated that Northern Ireland must follow EU medicine regulations. Following updated guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) earlier this month, the medicines regulator has announced that UK licensing of medicines will be split into the following regional categories:

UK – including both Great Britain and Northern Ireland

GB – Great Britain ONLY and excluding Northern Ireland-only products

NI – Northern Ireland only and excluding Great Britain-only products.

In light of this, C+D Data has developed one unique PIP code per unique product/medicine listing, to be used across the UK supply chain to facilitate unique identification, ordering, wholesale, distribution, and returns.

To read more:

<https://www.chemistanddruggist.co.uk/CD135921/CD-Data-provides-new-PIP-codes-for-Northern-Ireland-postBrexit>

## MEDICAL DEVICES MAY BE LIMITED FROM ENTERING THE UK

Difficulties with marketing medical devices in the UK and EU may deter manufacturers from launching new products in the UK.

Geopolitical events such as Brexit can lead to profound effects on local, regional and global healthcare markets. The UK's withdrawal from the European Union (EU), prompted a period of uncertainty in the country's healthcare market during the transitional years. There is speculation over potential price increases in medical and healthcare supplies and disruptions in the supply chain.

To read more:

<https://www.medicaldevice-network.com/comment/new-regulations-brexit-medical-devices/>

## GENERICS AND BIOSIMILARS

The generic medicines industry is moving beyond making copies, to developing patent-expired products, using new formulations, dosages and delivery methods. Around 75% of all medicines in the UK are generic, making the UK one of the highest users of prescription generic medicines in Europe. Generics are the foundation of the UK health system as they deliver £13 billion in savings every year. Traditionally generic medicines have been perceived as merely copies of the original products. However, the generics of today are so much more than that.

To read more:

[https://www.pharmatimes.com/magazine/2022/januaryfebruary\\_2022/generics\\_and\\_biosimilars\\_innovation\\_not\\_imitation](https://www.pharmatimes.com/magazine/2022/januaryfebruary_2022/generics_and_biosimilars_innovation_not_imitation)

## MODERNA INTEREST IN UK FACILITY

Moderna is reportedly in late-stage negotiations with the UK government that could result in a new research and manufacturing facility being set up in the biotech 'golden triangle' between London, Oxford and Cambridge. The development has been prompted by a desire on the behalf of the US biotech to collaborate with the NHS, according to a report in the Financial Times.


The government is hoping access to NHS patients for clinical testing as well as the UK's academic expertise will be a draw for biopharma companies and encourage inward investment.

To read more

<https://pharmaphorum.com/news/nhs-said-to-be-central-to-moderna-interest-in-uk-facility/>

## GENERIC PRODUCT PRICE BOUNCES

Price bounces happen after the originator product (Migard Tabs 2.5mg 6 in this case) loses its exclusivity (LOE) and generics have been launched. The market price of the generic can fall very quickly if there are lots of generic licence holders. However, where product prices fall very rapidly, licence holders can see the market rate fall below a point at which they can make a profit. At this point the remaining stock in the market becomes more valuable as the amount available to supply pharmacies declines. These price bounces happen very frequently, and can give opportunities for the originator product to fill the supply gap. They also prompt the DHSC (Dept. of Health and Social Care), in consultation with the PSNC (Pharmaceutical Services Negotiating Committee) to grant price concessions so that pharmacies can still make a profit on dispensing these products.



## ANTIHISTAMINES MAY HELP WITH LONG COVID

Long COVID is a chronic condition when patients have persistent symptoms that extend beyond the typical time frame. The effects of COVID-19 on individuals can range from mild symptoms to several weeks of illness, but various ailments including brain fog, joint pain and fatigue can last for months after the initial infection - collectively known as long COVID. Could antihistamines help with long COVID? Scientists launch study after healthcare worker took pills by accident and her symptoms eased. According to a recently published case report, two healthy females have returned to almost their normal daily activities after taking daily antihistamines for long COVID.

To read more:

<https://www.dailymail.co.uk/news/article-10507429/Antihistamines-help-resolve-long-COVID-scientists-believe-Treatment-discovered-accident.html>

## SPIKE IN PRICE CONCESSIONS PROMPTS CONCERN OVER GENERIC MEDICINE SUPPLY

As the number of price concessions for generic drugs soared in January 2022, the Pharmaceutical Services Negotiating Committees has raised concerns with the government over supply issues. The Pharmaceutical Journal has been told by the Pharmaceutical Services Negotiating Committee (PSNC) that Medicine supply issues are behind a rise in generic medicines prices. Contractors are reporting problems obtaining more and more drugs, with a number of complex factors at play in the supply chain once again.

To read more:

<https://pharmaceutical-journal.com/article/news/spike-in-price-concessions-prompts-concern-over-generic-medicine-supply-issues>

## INFLUX OF PHARMACIES FOR SALE

Pharmacy prices could come under “slight pressure” this year if an “unexpected influx” of pharmacy properties enters the market, a brokerage has said. Prices should remain “stable” in 2022 as buyers’ confidence is expected to remain high. Support for pharmacy acquisitions remains positive, however, this stability could be rocked by any unexpected sales, the broker suggested in its market report.

To read more:

<https://www.chemistanddruggist.co.uk/CD135891/Unexpected-influx-of-pharmacies-for-sale-could-rock-market-broker-warns>

## PRICE WATCH UK... UK KICKS OFF 2022 WITH CELECOXIB AND RIZATRIPTAN RISES

UK average trade prices for certain presentations of celecoxib and rizatriptan trebled and even quadrupled in the first month of 2022, according to the latest figures from WaveData. Steep average price rises were seen for celecoxib and rizatriptan in the UK in the first month of 2022, according to the latest figures from WaveData, based on trade prices to UK independent pharmacists. Topping our table of Biggest Risers in January was celecoxib 200mg capsules in 30-count packs, which had only just been moved from our Recent Launches category after being replaced by isotretinoin 20mg capsules in 30-count packs that were added to Category M this month.

To see more go to <https://generics.pharmaintelligence.informa.com/> and view our article from this month’s Generics Bulletin.

WaveData

Subscribe to the industry's comprehensive source of news and analysis.  
[www.generics-bulletin.com](http://www.generics-bulletin.com)

**Generics Bulletin**   
Informa Pharma Intelligence

# WAVEDATA — TOP TEN SEARCHED PRODUCTS - WHERE THE FOCUS WAS TO FEBRUARY 2022

According to WaveData, these were the most commonly investigated products in searches of the online pricing data Wavedata Live accessed through [www.wavedata.co.uk/login](http://www.wavedata.co.uk/login).

Both UK and PI prices were viewed for each product, giving some indication of where the focus was to February 2022. WaveData prices in the top 10 articles are averages.

Product	Nov-21	Dec-21	Jan-22	Feb-22
Amoxicillin Caps 500mg 21	£0.60	£0.72	£1.78	£2.02
Omeprazole Caps 20mg 28	£0.42	£0.42	£0.41	£0.55
Losartan Tabs 100mg 28	£0.92	£2.00	£4.38	£4.76
Losartan Tabs 50mg 28	£0.71	£1.79	£3.11	£3.55
Losartan Tabs 25mg 28	£0.57	£1.28	£2.42	£2.53
Paracetamol Caplets 500mg 100	£1.01	£0.96	£0.96	£0.99
Sertraline Tabs 50mg 28	£0.64	£0.61	£0.59	£0.60
Atorvastatin Tabs 20mg 28	£0.54	£0.51	£0.49	£0.50
Citalopram Tabs 20mg 28	£0.34	£0.37	£0.39	£0.49
Orlistat Caps 120mg 84	£26.78	£26.68	£27.02	£26.21

This bulletin now goes out to 5500 plus people.

If you would like to add or suggest any articles or comments, please let me know by the 23rd March 2022, as I will be issuing the next bulletin on the 30th March 2022.

If you have any colleagues who would like to receive this, please let them know about it. You can view all copies of the Bulletin at <https://www.wavedata.co.uk/kb/>

Jackie Moss  
WaveData Ltd  
E-mail: [bulletin@wavedata.co.uk](mailto:bulletin@wavedata.co.uk)  
Twitter @wavedata  
LinkedIn: <https://www.linkedin.com/company/wavedata-ltd/>



# FUTURE EVENTS

Organizer	Date	Venue	a/t
Priorities for diagnostics and medical technology	1st Mar 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Diagnostics-22">https://www.westminsterforumprojects.co.uk/book/Diagnostics-22</a>
The International Rare Disease Showcase	1st - 3rd Mar 22	Online	<a href="https://www.findacure.org.uk/rare-disease-showcase/">https://www.findacure.org.uk/rare-disease-showcase/</a>
AAC Industry Engagement Event	1st & 3rd Mar 22	Online	<a href="http://www.emig.org.uk">www.emig.org.uk</a>
Next steps for mental health policy in NI	8th Mar 22	Online	<a href="https://www.policyforumforni.co.uk/book/Mental-Health-NI-22">https://www.policyforumforni.co.uk/book/Mental-Health-NI-22</a>
EMIG HR Group Webinar	8th Mar 22	Online	<a href="mailto:drjim.golby@applied-driving.com">drjim.golby (a/t) applied-driving.com</a>
Priorities for general practice and recovery from COVID-19	9th Mar 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/General-Practice-21">https://www.westminsterforumprojects.co.uk/book/General-Practice-21</a>
PM Society Careers Conference	9th Mar 22	London	<a href="https://pmsociety.org.uk/event/pm-society-careers-event-a-career-in-pharmaceuticals/">https://pmsociety.org.uk/event/pm-society-careers-event-a-career-in-pharmaceuticals/</a>
Next steps for dementia diagnosis, care & research in England - discussion relevant to pharma	16th Mar 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Dementia-22">https://www.westminsterforumprojects.co.uk/book/Dementia-22</a>
Build Market Advantage: The Priorities of the NHS in 2022/23	18th Mar 22	Online	<a href="https://marketaccesstraining.co.uk/event/the-priorities-of-the-nhs-in-2022-23-with-paul-oconnor/#tribe-tickets">https://marketaccesstraining.co.uk/event/the-priorities-of-the-nhs-in-2022-23-with-paul-oconnor/#tribe-tickets</a>
EMIG Compliance Meeting	21st Mar 22	London	<a href="https://www.legalzoom.com/meeting/register/tZUlfurrrTouGdW_WCrDovBMPV_h0ts9iZqK">https://www.legalzoom.com/meeting/register/tZUlfurrrTouGdW_WCrDovBMPV_h0ts9iZqK</a>
Long Covid - improving patient care and access to support, progress in service development, and priority areas for research	22nd Mar 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Long-COVID-2022">https://www.westminsterforumprojects.co.uk/book/Long-COVID-2022</a>
EMIG Digital Health Webinar	22nd Mar 22	Online	<a href="mailto:jill.payne@emig.org.uk">jill.payne (a/t) emig.org.uk</a>
EMIG Wales Webinar	24th Mar 22	Online	<a href="mailto:jill.payne@emig.org.uk">jill.payne (a/t) emig.org.uk</a>
EUnethTA 21 meeting for Health Technology Developers on Joint Clinical Assessments production	25th Mar 22	Online	<a href="https://www.eventbrite.co.uk/e/eunethta-21-meeting-for-htd-on-jcaca-production-for-pharma-md-tickets-261685246617">https://www.eventbrite.co.uk/e/eunethta-21-meeting-for-htd-on-jcaca-production-for-pharma-md-tickets-261685246617</a>
Utilising AI-driven technologies within health & social care - discussion relevant to pharma	28th Mar 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/AI-in-Health-22">https://www.westminsterforumprojects.co.uk/book/AI-in-Health-22</a>
Introduction to Healthcare Business Development	30th Mar - 1st Apr 22	London or Online	<a href="https://plg-group.com/training/introductory-training-course/">https://plg-group.com/training/introductory-training-course/</a>
PLG Business Development Awards	31st Mar 22	London	<a href="https://plg-group.com/events/plg-business-development-awards-2022/">https://plg-group.com/events/plg-business-development-awards-2022/</a>
New conference on UK sustainable health services - discussion relevant to pharma	21st Apr 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Net-Zero-Health-22">https://www.westminsterforumprojects.co.uk/book/Net-Zero-Health-22</a>
Next steps for cardiovascular research, prevention and care in England	28th Apr 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Cardiovascular-22">https://www.westminsterforumprojects.co.uk/book/Cardiovascular-22</a>
Use of patient records and data	29th Apr 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Patient-Records-22">https://www.westminsterforumprojects.co.uk/book/Patient-Records-22</a>
The 3rd Int'l Congress on Controversies on Cannabis-Based Medicines,	12th - 13th May 22	Demark	<a href="https://med-cannabis2022.com/registration/">https://med-cannabis2022.com/registration/</a>
Priorities for integrated health and social care in England	8th June 22	Online	<a href="https://www.westminsterforumprojects.co.uk/book/Integrated-Care-22">https://www.westminsterforumprojects.co.uk/book/Integrated-Care-22</a>
Cannabis Business Europe 2022	21st - 22nd June 22	Germany	<a href="https://www.worldclassbusinessleaders.com/events/CBE22">https://www.worldclassbusinessleaders.com/events/CBE22</a>